Volume 21, Number 1—January 2015
CME ACTIVITY - Research
Clinical Course and Long-Term Outcome of Hantavirus-Associated Nephropathia Epidemica, Germany
Medscape, LLC is pleased to provide online continuing medical education (CME) for this journal article, allowing clinicians the opportunity to earn CME credit.
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Medscape, LLC designates this Journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at http://www.medscape.org/journal/eid; (4) view/print certificate.
Release date: December 16, 2014; Expiration date: December 16, 2015
Upon completion of this activity, participants will be able to:
• Describe clinical characteristics of acute nephropathia epidemica associated with Puumala virus hantavirus infection, based on a cross-sectional prospective survey.
• Distinguish long-term sequelae of acute nephropathia epidemica associated with Puumala virus hantavirus infection.
• Discuss serologic findings of nephropathia epidemica associated with Puumala virus hantavirus infection.
Claudia Chesley, Technical Writer/Editor, Emerging Infectious Diseases. Disclosure: Claudia Chesley has disclosed no relevant financial relationships.
Laurie Barclay, MD, freelance writer and reviewer, Medscape, LLC. Disclosure: Laurie Barclay, MD, has disclosed no relevant financial relationships.
Disclosures: Joerg Latus, MD; Matthias Schwab, MD; Evelina Tacconelli, MD; Friedrich-Michael Pieper; Daniel Wegener, MD; Juergen Dippon, PhD; Simon Müller, PhD; David Zakim, MD; Daniel Kitterer, MD; Martin Priwitzer, MD; Barbara Mezger; Birgit Walter-Frank, MD; Angela Corea, MD; Albrecht Wiedenmann, MD; Stefan Brockmann, MD; Christoph Pöhlmann, MD, MS; M. Dominik Alscher, MD, CMO; and Niko Braun, MD, have disclosed no relevant financial relationships. Stephan Segerer, MD, has disclosed the following relevant financial relationships: served as an advisor or consultant for Roche; Baxter; served as a speaker or member of a speakers bureau for Roche; Baxter.>
- Page created: December 17, 2014
- Page last updated: December 17, 2014
- Page last reviewed: December 17, 2014
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)